Advertisement
BDX vs COO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. The Cooper Companies (COO) Stock Comparison
Key Takeaways
- BDX operates in broader medical technology segments including drug delivery and diagnostics, while COO focuses on vision care and surgical products, creating distinct sector exposures.
- Recent market activity shows BDX benefiting from AI-related partnerships and international product launches, supporting steadier sentiment compared to COO's more variable earnings responses.
- BDX has delivered approximately 20% returns over the past year amid portfolio adjustments, whereas COO reported solid quarterly revenue growth but faces valuation scrutiny amid slower organic trends.
- Risk factors differ: BDX contends with cash flow considerations post-business separations, while COO navigates litigation impacts and regional demand fluctuations in China.
- Market positioning highlights BDX's larger scale and dividend yield versus COO's emphasis on premium product uptake and consecutive earnings beats.
- Relative performance in recent weeks reflects healthcare sector resilience, with both stocks showing resilience yet differentiated by growth drivers and analyst outlooks.
Introduction
This comparison examines BDX and COO, two established players in the healthcare equipment and supplies industry. Investors and traders seeking to understand relative performance, business model contrasts, and sentiment shifts within the medical technology sector may find this analysis relevant. The review draws on verifiable developments from recent market activity to highlight trade-offs in stability, growth drivers, and positioning without forecasting outcomes.
BDX Overview and Recent Performance
Becton, Dickinson and Company manufactures and sells medical devices, instrument systems, and reagents focused on medication management, infection prevention, and diagnostic solutions. In recent weeks, the stock has reflected positive influences from AI adoption initiatives and expanded access to GLP-1 therapies in Brazil through partnerships. Broader market activity shows the shares trading near $165 with a market capitalization around $47 billion and a dividend yield near 2.5%. Performance over the past year reached approximately 20%, supported by demand in drug-delivery devices, though earlier portfolio optimizations including a biosciences unit sale introduced temporary adjustments to earnings guidance. Sentiment has remained measured amid ongoing cash flow considerations.
COO Overview and Recent Performance
The Cooper Companies, Inc. develops and manufactures products for vision care through its CooperVision segment and surgical solutions via CooperSurgical. Recent market activity includes second-quarter results showing revenue of $1.082 billion, an 8% year-over-year increase with 5% organic growth, alongside a non-GAAP earnings per share beat. The stock trades near $72 with a market capitalization around $14 billion. Over the past year, returns have been more modest at roughly 2%, with shares fluctuating between a 52-week low near $59 and high near $90. Influences include premium product adoption and contract wins offset by regional softness, contributing to steady but cautious investor sentiment in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a broader library of hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this focused section. Available bots span diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical win rates, drawdowns, and profitability statistics varying widely by bot. This variety allows users to explore options suited to different risk tolerances and market environments. For further details on current trending selections, visit the Trending AI Robots page.
Head-to-Head Comparison
BDX and COO differ markedly in business models: BDX emphasizes diversified medical technology across multiple therapeutic areas with greater scale, while COO concentrates on specialized vision and surgical niches. Growth drivers for BDX include international expansions and technology integrations, contrasting with COO’s reliance on organic uptake in premium segments. Recent momentum favors BDX’s steadier trajectory amid AI catalysts, whereas COO exhibits stronger quarterly beats but higher valuation sensitivity. Risk factors encompass BDX’s post-separation cash flow dynamics versus COO’s litigation and regional exposure. Sector exposure remains healthcare-oriented for both, yet sentiment reflects BDX’s larger market presence alongside COO’s focused execution.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning in recent market activity, Tickeron’s AI would currently assign a probabilistic edge to BDX due to its broader diversification and emerging technology catalysts. COO demonstrates competitive quarterly execution but faces more pronounced valuation and regional considerations. This assessment remains subject to ongoing market developments and does not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Buy and COO is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 2 FA rating(s) are green whileCOO’s FA Score has 1 green FA rating(s).
- BDX’s FA Score: 2 green, 3 red.
- COO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 5 TA indicator(s) are bullish while COO’s TA Score has 4 bullish TA indicator(s).
- BDX’s TA Score: 5 bullish, 4 bearish.
- COO’s TA Score: 4 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +3.70% price change this week, while COO (@Pharmaceuticals: Other) price change was +2.61% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.26%. For the same industry, the average monthly price growth was +8.63%, and the average quarterly price growth was +6.97%.
Reported Earning Dates
BDX is expected to report earnings on Nov 05, 2026.
COO is expected to report earnings on Sep 09, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.26% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BDX | COO | BDX / COO | |
| Capitalization | 50B | 14.9B | 336% |
| EBITDA | 4.97B | 890M | 558% |
| Gain YTD | 21.791 | -7.064 | -308% |
| P/E Ratio | 31.73 | 64.55 | 49% |
| Revenue | 22.2B | 4.23B | 525% |
| Total Cash | N/A | 139M | - |
| Total Debt | 17.3B | 2.46B | 703% |
BDX | COO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 89 | 100 | |
SMR RATING 1..100 | 86 | 89 | |
PRICE GROWTH RATING 1..100 | 14 | 45 | |
P/E GROWTH RATING 1..100 | 62 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (7) in the Medical Specialties industry is somewhat better than the same rating for COO (67). This means that BDX’s stock grew somewhat faster than COO’s over the last 12 months.
BDX's Profit vs Risk Rating (89) in the Medical Specialties industry is in the same range as COO (100). This means that BDX’s stock grew similarly to COO’s over the last 12 months.
BDX's SMR Rating (86) in the Medical Specialties industry is in the same range as COO (89). This means that BDX’s stock grew similarly to COO’s over the last 12 months.
BDX's Price Growth Rating (14) in the Medical Specialties industry is in the same range as COO (45). This means that BDX’s stock grew similarly to COO’s over the last 12 months.
COO's P/E Growth Rating (10) in the Medical Specialties industry is somewhat better than the same rating for BDX (62). This means that COO’s stock grew somewhat faster than BDX’s over the last 12 months.
| BDX | COO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 61% | 1 day ago 47% |
| Stochastic ODDS (%) | 1 day ago 46% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 50% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 51% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 50% | 1 day ago 51% |
| Advances ODDS (%) | 4 days ago 44% | 5 days ago 55% |
| Declines ODDS (%) | 24 days ago 43% | 1 day ago 60% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 55% |
| Aroon ODDS (%) | 1 day ago 51% | 1 day ago 54% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +0.79% | ||
| COO - BDX | 54% Loosely correlated | -0.56% | ||
| BAX - BDX | 51% Loosely correlated | -1.18% | ||
| TMO - BDX | 50% Loosely correlated | -1.28% | ||
| CNMD - BDX | 48% Loosely correlated | +1.18% | ||
| SOLV - BDX | 47% Loosely correlated | +2.46% | ||
More | ||||
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.
| Ticker / NAME | Correlation To COO | 1D Price Change % | ||
|---|---|---|---|---|
| COO | 100% | -0.56% | ||
| BDX - COO | 56% Loosely correlated | +0.79% | ||
| A - COO | 50% Loosely correlated | -0.51% | ||
| MMSI - COO | 46% Loosely correlated | +0.29% | ||
| DHR - COO | 46% Loosely correlated | -0.71% | ||
| ICUI - COO | 44% Loosely correlated | -0.07% | ||
More | ||||